Moderna Defends Judicial Decision to Restrict Patent Litigation on COVID-19 Vaccine

In a recent legal maneuver, Moderna has asserted that a federal judge should disregard a competing mRNA developer’s plea to reassess his decision that limits discussions in a patent lawsuit regarding Moderna’s COVID-19 vaccines. Moderna argues that the rival party is attempting to introduce new arguments at an inopportune moment. This case highlights the intricate dynamics of pharmaceutical patent disputes amid the global pandemic response. More details can be found in the Law360 coverage.